Related Experiment Video
Updated: May 5, 2026

Detection of microRNA Expression in Peritoneal Membrane of Rats Using Quantitative Real-time PCR
Published on: June 27, 2017
Renal fibrosis: not just PAI-1 in the sky
1Department of Pathology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA. agnes.fogo@vanderbilt.edu
Abstract:
A delicate balance exists between ECM synthesis and degradation such that interruption of the corresponding pathways results in increased plasminogen activator inhibitor-1 (PAI-1), pathological matrix accumulation, and glomerulosclerosis. A new study demonstrates that therapy with a mutant PAI-1 increases matrix turnover and reduces glomerulosclerosis by competing with endogenous PAI-1, suggesting therapeutic utility in the treatment of fibrotic renal disease.
Related Concept Videos
Pericarditis I: Introduction
Cirrhosis II: Pathophysiology
Chronic Pancreatitis I: Introduction
Chronic Pancreatitis II: Pathophysiology

